Chronic lymphocytic leukemia (CLL) treatment: So many options, great choices.
The availability of many novel targeted therapies—ibrutinib, idelalisib, duvelisib, and venetoclax—has markedly improved the management of chronic lymphocytic leukemia, allowing for risk‑based, tailored treatment plans.
Chronic lymphocytic leukemia (CLL) has seen a paradigm shift in the past decade owing to the introduction of several targeted therapies, including ibrutinib, idelalisib, duvelisib, and venetoclax. These agents enable precise, risk‑based treatment regimens, improving clinical outcomes. Nonetheless, CLL remains incurable and presents ongoing challenges for clinicians.
Targeted agents have transformed CLL from a disease of limited therapeutic options into one where therapy can be personalized, improving survival and quality of life.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)